PI3K
OnKure Raises $65M in Private Placement, Closes Merger with Reneo Pharmaceuticals
After the latest funding and merger, OnKure will have enough resources to support operations into Q4 2026, including development of its PI3Kα inhibitors.
Relay Advancing Mutant PI3Kα Inhibitor into Phase III Breast Cancer Trial
The company said interim data from a Phase I trial of RLY-2608 plus fulvestrant support moving the program into a pivotal study in 2025.
Scorpion Therapeutics Raises $150M in Series C Funding
The firm will use the proceeds to advance its lead candidate, the PI3Kα inhibitor STX-478, and two EGFR programs.
Relay, Pfizer Testing CDK4, PI3Kα Inhibitors in Metastatic Breast Cancer Trial
Relay further disclosed a program in vascular malformations and an NRAS-selective inhibitor that it is planning to bring into clinical development in 2025.
BridgeBio Launches Precision Oncology Spinoff With $200M in Funding
BridgeBio Oncology Therapeutics will launch with three precision oncology programs targeting KRAS and PI3K.
Dec 29, 2023
Best Precision Medicine Stories of 2023
Oct 18, 2023
Celcuity to Raise $50M in Private Placement
Jul 30, 2021
Dec 15, 2020